Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss
March 8th, 2008
Acceleron Pharma, Inc. and Celgene Corporation announced a worldwide strategic collaboration for the joint development and commercialization of ACE-011, a first-in-class, novel bone-forming compound. The collaboration combines both companies' resources and commitment to developing products for the treatment of cancer and cancer-related bone loss. In pre-clinical and early clinical studies, this innovative compound has reported success in key biomarkers of bone formation. The companies also signed an option agreement for certain discovery stage programs. Under the terms of the agreement, Celgene and Acceleron will jointly develop, manufacture and commercialize...
Source: Law & Health Weekly (2008-03-08)
|
